chemieunternehmen.com

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5184

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-first-nine-months-2013-results-5183

Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer’s disease drug discovery and development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-targetad-collaboration-with-johnson–johnson-innovation-to-identify-and-develop-novel-alzheimers-disease-therapies-5181

Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-leukemia–lymphoma-society-enter-into-a-strategic-research-collaboration-5177

Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-first-milestones-in-multi-target-deal-with-ucb-5175

Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-integrated-alliance-with-astrazeneca-in-kidney-disease-5173

Evotec AG today announced the publication of its fourth DDup edition. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-4—epigenetics-5170

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-hold-rd-day-2013-5169

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-harvard-university-to-collaborate-on-exploration-of-enteroendocrine-signals-affecting-key-metabolic-pathways-5165